ATE472337T1 - Pharmazeutische zusammensetzung aus f(ab) 2- fragmenten von antikörpern und verfahren zu ihrer herstellung - Google Patents

Pharmazeutische zusammensetzung aus f(ab) 2- fragmenten von antikörpern und verfahren zu ihrer herstellung

Info

Publication number
ATE472337T1
ATE472337T1 AT02703990T AT02703990T ATE472337T1 AT E472337 T1 ATE472337 T1 AT E472337T1 AT 02703990 T AT02703990 T AT 02703990T AT 02703990 T AT02703990 T AT 02703990T AT E472337 T1 ATE472337 T1 AT E472337T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
antibodies
fragments
production
free
Prior art date
Application number
AT02703990T
Other languages
English (en)
Inventor
Lopez De Silanes Juan
Mancilla Nava Rita
F Paniagua Solis Jorge
Original Assignee
Inst Bioclon S A De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25172478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE472337(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Bioclon S A De Cv filed Critical Inst Bioclon S A De Cv
Application granted granted Critical
Publication of ATE472337T1 publication Critical patent/ATE472337T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
AT02703990T 2001-02-28 2002-02-28 Pharmazeutische zusammensetzung aus f(ab) 2- fragmenten von antikörpern und verfahren zu ihrer herstellung ATE472337T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/798,076 US6709655B2 (en) 2001-02-28 2001-02-28 Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
PCT/MX2002/000013 WO2002068475A2 (es) 2001-02-28 2002-02-28 Composicion farmaceutica de fragmentos f(ab)2 de anticuerpos y un proceso para su preparacion

Publications (1)

Publication Number Publication Date
ATE472337T1 true ATE472337T1 (de) 2010-07-15

Family

ID=25172478

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02703990T ATE472337T1 (de) 2001-02-28 2002-02-28 Pharmazeutische zusammensetzung aus f(ab) 2- fragmenten von antikörpern und verfahren zu ihrer herstellung

Country Status (11)

Country Link
US (4) US6709655B2 (de)
EP (1) EP1374895B1 (de)
AT (1) ATE472337T1 (de)
AU (1) AU2002237586B8 (de)
CA (1) CA2443391C (de)
DE (1) DE60236853D1 (de)
DK (1) DK1374895T3 (de)
ES (1) ES2345245T3 (de)
HK (1) HK1063057A1 (de)
MX (1) MXPA03007992A (de)
WO (1) WO2002068475A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709655B2 (en) * 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
DE60331413D1 (de) * 2002-01-18 2010-04-08 Takeda Pharmaceutical Natrium abhängiger Gallensäure Transporter und dessen Verwendung
US7335759B2 (en) * 2002-12-02 2008-02-26 Universidad Nacional Autónoma de Méxica (UNAM) Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides
MXPA06000965A (es) * 2003-07-25 2007-05-04 Silanes Sa De Cv Lab Administracion de fragmentos f(ab??)2 de anticuerpos anti-citocinas.
FR2859725B1 (fr) 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
US7381802B2 (en) * 2005-04-15 2008-06-03 Universidad Nacional Autónoma De México (UNAM) Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
MX367136B (es) 2012-10-18 2019-08-06 Inosan Biopharma S A Star Proceso para purificar fragmentos de anticuerpos polivalentes derivados de plasma hiperinmune.
EP3612298A4 (de) 2017-04-20 2020-11-11 Tubemaster, Inc. Verfahren zum laden von pellets
WO2019070108A1 (es) 2017-10-02 2019-04-11 Laboratorios Silanes S.A. De C.V. Proceso de alto rendimiento para la producción de antivenenos de fragmentos f (ab') 2 de anticuerpos
EP4337689A1 (de) 2021-05-12 2024-03-20 Applied Biomedical Science Institute Bindungspolypeptide gegen sars cov-2 und verwendungen davon

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401663A (en) * 1981-06-30 1983-08-30 The Procter & Gamble Company Novel sulfonamide derivatives
US4443473A (en) 1981-06-30 1984-04-17 The Procter & Gamble Company Carbamate derivatives
US4424205A (en) 1982-03-18 1984-01-03 The Procter & Gamble Company Hydroxyphenylacetamides having analgesic and anti-irritant activity
US4849352A (en) 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
US4940670A (en) 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
US4806346A (en) * 1986-12-16 1989-02-21 American Home Products Corporation Method for isolation of antigen specific immunoglobulin
US4814433A (en) 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
US5328834A (en) 1989-09-08 1994-07-12 Unisyn Technologies, Inc. Method for preparing immunoglobulin fragments
US5196193A (en) * 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
GB9109478D0 (en) * 1991-05-02 1991-06-26 Therapeutic Antibodies Inc Antivenoms
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
ES2138662T3 (es) 1993-06-03 2000-01-16 Therapeutic Antibodies Inc Produccion de fragmentos de anticuerpos.
US20030228310A1 (en) * 1996-12-23 2003-12-11 Advanced Biotherapy, Inc. Treatment of skin diseases
US20030223995A1 (en) * 1996-12-23 2003-12-04 Advanced Biotherapy, Inc. Treatment of pemphigus vulgaris
AU1521000A (en) 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
EP1035209A1 (de) 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stabile rekombinante Influenzaviren, die frei von Helfervirus sind
AU4230900A (en) * 1999-04-08 2000-10-23 General Hospital Corporation, The Purposeful movement of human migratory cells away from an agent source
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
WO2001058469A1 (en) 2000-02-08 2001-08-16 Wax Martin B Methods for treating glaucoma
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
US6534059B2 (en) * 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US20040086508A1 (en) * 2001-06-05 2004-05-06 Advanced Biotherapy, Inc. Treatment of organ transplant rejection
US20040062768A1 (en) * 2001-06-05 2004-04-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US20030180294A1 (en) 2002-02-22 2003-09-25 Devries Gerald W. Methods of extending corneal graft survival
US6733742B1 (en) * 2002-12-26 2004-05-11 Chevron U.S.A. Inc. Molecular sieve SSZ-63 composition of matter and synthesis thereof
MXPA06000965A (es) 2003-07-25 2007-05-04 Silanes Sa De Cv Lab Administracion de fragmentos f(ab??)2 de anticuerpos anti-citocinas.
US7381802B2 (en) 2005-04-15 2008-06-03 Universidad Nacional Autónoma De México (UNAM) Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom

Also Published As

Publication number Publication date
EP1374895B1 (de) 2010-06-30
EP1374895A2 (de) 2004-01-02
DE60236853D1 (de) 2010-08-12
US8075893B2 (en) 2011-12-13
WO2002068475A3 (es) 2002-10-31
WO2002068475A2 (es) 2002-09-06
CA2443391A1 (en) 2002-09-06
US20090142356A1 (en) 2009-06-04
DK1374895T3 (da) 2010-10-11
US7485303B2 (en) 2009-02-03
US20040166107A1 (en) 2004-08-26
AU2002237586A1 (en) 2002-09-12
US20020164327A1 (en) 2002-11-07
US6709655B2 (en) 2004-03-23
HK1063057A1 (en) 2004-12-10
US8512706B2 (en) 2013-08-20
AU2002237586B8 (en) 2007-01-04
ES2345245T3 (es) 2010-09-20
CA2443391C (en) 2012-04-24
AU2002237586B2 (en) 2006-12-21
MXPA03007992A (es) 2004-09-29
US20120064063A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
DE69840412D1 (de) Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
BR9713521A (de)
WO2003059935A3 (en) Methods for purifying protein
EE05309B1 (et) β-Amloidpeptiidi „ratundvad humaniseeritud antikehad, meetod nende valmistamiseks, nende kasutamine ja farmatseutiline kompositsioon
ATE165395T1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
WO2002079232A3 (en) Reducing the immunogenicity of fusion proteins
DE69830315D1 (de) Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
WO2003048207A3 (en) Anti-dota antibody
ATE472337T1 (de) Pharmazeutische zusammensetzung aus f(ab) 2- fragmenten von antikörpern und verfahren zu ihrer herstellung
ATE328611T1 (de) Multiple,kohlenhydrathaltige glycopeptid-antigene,daraus entwickelte impfstoffe sowie deren verwendung
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
ATE366746T1 (de) Gegen das semp1-protein gerichtete antikörper, verfahren zu deren herstellung, und deren anwendungen
PT856520E (pt) Metodo de preparacao de um anticorpo monoclonal, anticorpo monoclonal, uma composicao farmaceutica e um reagente de diagnostico
EE200500012A (et) Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks
WO2002060954A8 (en) Materials and methods for treatment of hepatitis c
WO2003026700A3 (fr) Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
ATE338819T1 (de) Antigenes protein aus malassezia
ATE111455T1 (de) 3-substituierte 1,2,3,4-oxatriazol-5- iminderivate, verfahren zur herstellung sowie diese enthaltende arzneimittel.
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
AU7546500A (en) Designing immunogens
ATE144286T1 (de) Monoklonale antikörper gegen den plasmin- antiplasmin komplex, verfahren zu ihrer herstellung sowie ihre verwendung
WO2001092321A3 (en) Proteins involved in cytoadhesion of plasmodium falciparum ring-stage-infected erythrocytes
WO1999019358A3 (de) Antikörper gegen baculoviren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1374895

Country of ref document: EP